首页> 外国专利> treatment of hepatitis c virus infections with telaprevir (vx-950) in patients unresponsive to treatment with pegylated interferon alfa-2a / 2b and ribavirin

treatment of hepatitis c virus infections with telaprevir (vx-950) in patients unresponsive to treatment with pegylated interferon alfa-2a / 2b and ribavirin

机译：替拉普韦（vx-950）治疗聚乙二醇干扰素alfa-2a / 2b和利巴韦林对丙型肝炎病毒感染的治疗

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.

机译：本发明涉及用于治疗或预防患者的丙型肝炎感染的抗病毒疗法和组合物，并且涉及本文公开的其他方法。本发明还涉及包含组合物和剂型的试剂盒和药物包装。本发明还涉及制备这些组合物，剂量，试剂盒和包装的方法。

著录项

公开/公告号BRPI0911673A2

专利类型
公开/公告日2017-12-05

原文格式PDF
申请/专利权人 VERTEX PHARMACEUTICALS INCORPORATED;
展开▼

申请/专利号BR2009PI11673
发明设计人 IRA JACOBSON;JOHN MCHUTCHISON;LINDSAY MCNAIR;
展开▼

申请日2009-04-23
分类号A61K31/13;A61K31/454;A61K31/7056;A61K31/7072;A61K38/21;A61P1/16;A61P31/12;A61P31/14;
国家 BR
入库时间 2022-08-21 12:53:16

相似文献

专利
外文文献
中文文献